PARP inhibitors in recent years have significantly improved care for ovarian cancer. However, not all patients benefit and some develop resistance over time.
Acute generalized exanthematous pustulosis (AGEP) presents with sterile pustules and systemic symptoms, and usually improves within days of stopping the trigger.
